Stability-indicating HPTLC method for quantitative estimation of silybin in bulk drug and pharmaceutical dosage form

Biomedical Chromatography

Volumn 24, Issue 6, 2010, Pages 639-647

  Parveen, Rabea ^a   Ahmad, Sayeed ^a   Baboota, Sanjula ^a   Ali, Javed ^a   Alka, Ahuja ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Degradation kinetics; HPTLC; Silybin; Silymarin nanoemulsion; Stability indicating

Indexed keywords

ABSORBANCE; ACTIVATION ENERGY; CHLORINE COMPOUNDS; DEGRADATION; DRUG DOSAGE; FLAVONOIDS; ORGANIC SOLVENTS; SILICA; STABILITY; THIN LAYER CHROMATOGRAPHY;

BULK DRUGS; DEGRADATION KINETICS; DRUG DOSAGE FORM; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; NANOEMULSION; QUANTITATIVE ESTIMATION; SILYBIN; SILYMARIN; SILYMARIN NANOEMULSION; STABILITY-INDICATING;

ACETONE;

ACETONE; CHLOROFORM; FORMIC ACID; HYDROCHLORIC ACID; HYDROGEN PEROXIDE; SILIBININ; SILICON DIOXIDE; SILYBON; SILYMARIN; SODIUM HYDROXIDE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG PURITY; DRUG STABILITY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; NANOEMULSION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SHELF LIFE; THERMOSTABILITY;

EID: 77952762510     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1340     Document Type: Article

References (17)

1. Ahmad S, Ahmad R, Parveen R, Mujeeb M and Aquil M. A validated stability-indicating TLC method for determination of forskolin in crude drug and pharmaceutical dosage form. Chromatographia 2008; 67: 441-447.
2. Ansari MJ, Ahmad S, Kohli K, Ali J and Khar RK. Stability-indicating HPTLC determination of curcumin in bulk drug and pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis 2005; 39: 132-138. (Pubitemid 41112129)
3. Dehmlow C, Erhard J and de-Groot H. Inhibition of kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23: 749-754. (Pubitemid 26111988)
4. Ding T, Tian S, Zhang Z, Gu D, Chen Y, Shi Y and Sun Z. Determination of active component in silymarin by RP-LC and LC/MS. Journal of Pharmaceutical and Biomedical Analysis 2001; 26: 155-161. (Pubitemid 32635293)
5. Dixit N, Baboota S, Kohli K, Ahmad S and Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian Journal of Pharmacology 2007; 39: 171-179. (Pubitemid 350005989)
6. Guinea LMC and Pizarro SA. Analysis of silymarin in pharmaceutical preparations by TLC-photodensitometry. Anales de la Real Academia de Farmacia 1987; 53: 413-419.
7. Han YH, Lou HX, Ren DM, Sun LR, Ma B and Ji M. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. Journal of Pharmaceutical and Biomedical Analysis 2004; 34: 1071-1078. (Pubitemid 38296410)
8. ICH. Q2 (R1), Validation of analytical procedures: text and methodology. International Conference on Harmonization, Geneva, November 2005. Available from: http://www.ich.org/LOB/media/MEDIA417.pdf.
9. Kosina P, Kren V, Gebhardt R, Grambal F, Ulrichova J and Walterova D. Antioxidant properties of silybin glycosides. Phytotherapy Research 2002; 16: S33-S39.
10. Lee JI, Hsu BH, Wu D and Barrett JS. Separation and characterization of silybin, isosilybin, silydianin and silychristin in milk thistle extract by liquid chromatography-electrospray tandem mass spectrometry. Journal of Chromatography A 2006; 1116: 57-68. (Pubitemid 44287926)
11. Li W, Gao J, Hong-Zhi Z and Chang-Xiao L. Development of a HPLC-UV assay for silybin phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics 2006; 31: 265-270. (Pubitemid 46256270)
12. Muriel P, Garciapina T, Perez-Alvarez V and Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. Journal of Applied Toxicology 1992; 12: 439-442.
13. Pepping J. Milk thistle: Silybum marianum. American Journal of Health-System Pharmacy 1999; 56: 1195-1197.
14. Pradhan SC and Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian Journal of Medical Research 2006; 124: 491-504. (Pubitemid 46157708)
15. Rahman N, Ahmad Y and Azmi SNH. Optimized and validated kinetic spectrophotometric method for the determination of silymarin in drug formulations. Canadian Journal of Analytical Sciences and Spectroscopy 2005; 50: 116-129. (Pubitemid 41327685)
16. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK and Ali M. Development and Bio-availability assessment of ramipril nanoemulsion formulation. European Journal of Pharmaceutics and Biopharmaceutics 2007; 66: 227-243. (Pubitemid 46667230)
17. Wallace S, Carrier DJ, Beitle RR, Clausen EC and Griffis CL. HPLC-UV and LC-MS-MS characterization of silymarin in milk thistle seeds and corresponding products. Journal of Nutraceuticals, Functional and Medical Food 2003; 4: 37-48. (Pubitemid 37428675)